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Abstract
Introduction: Both genetic and clinical risk factors play roles in breast cancer onset. Developing
comprehensive and accurate breast cancer prediction model will enable effective identifications of
individuals at high risk, and facilitate personalized decision on screening and preventive strategy.
Objectives: Develop a risk prediction model for breast cancer including both genetic and clinical
risk factors, and quantify the benefit of adding polygenic risk score (PRS) in risk prediction.
Methods: Analysis was based on data collected through the UK Biobank which consists of 13,851
breast cancer cases and 206,865 controls. The clinical factors that we considered include baseline
demographics, lifestyles, family history, reproductive history, medication status and operation
history. The PRS for breast cancer was constructed from 2,994,056 single nucleotide
polymorphisms (SNPs) using the AnnoPred approach. The Area Under the Curve (AUC) was used
to evaluate the performance of different prediction models. The cumulative risk of breast cancer
was compared between participants in different risk groups.
Results: Breast cancer risk prediction based on AnnoPred derived PRS had a comparable
prediction accuracy (AUC=0.646, 95%CI 0.642-0.651) with that based on all the 19 clinical factors
(AUC=0.657, 95%CI 0.652-0.662). Combining PRS and clinical factors further improved the
prediction accuracy (AUC=0.708, 95%CI 0.704-0.713). Based on the combined model, the
estimated lifetime risk of developing breast cancer up to age 70 among individuals in the top 1%
risk group (40.1%) was more than 28-folds higher than that in the bottom 1% risk group (1.4%).
Conclusion: Breast cancer risk prediction based on genetic factors only can achieve comparable
performance compared to that using well established risk factors, demonstrating the significant
progress that has been made towards breast cancer genetics. It is important to include PRS in
deriving risk prediction for personalized breast cancer screening and prevention.
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Introduction
Breast cancer is the second most prevalent cancer in the world, and around 1.67 million women
were newly diagnosed with breast cancer in 2012 (Ferlay et al., 2015). As reported by the U.S.
Breast Cancer Statistics, breast cancer also has the second highest death rate after lung cancer, and
268,600 new invasive breast cancer in addition to 62,930 non-invasive breast cancer cases are
expected to be diagnosed in the year of 2019 (U.S. Breast Cancer Statistics, 2019). Various models
have been constructed in the past several decades aiming to identify women at elevated risk for
breast cancer based on risk factors, including age, obesity, family history, reproductive factors,
estrogen, and lifestyle, etc. (Hüsing et al., 2012) (Majeed et al., 2014) The fact that early detection
of breast cancer significantly improve the prognosis of the disease has further motivated the
development and advancement of these prediction models to improve survival time for women.

The Gail model was the first established BC risk prediction model, which includes six risk factors:
age, age at first live birth, age at menarche, history of breast cancer in first-degree relatives, number
of previous breast biopsies, and history of atypical hyperplasia, most of which are reproductive
factors (Gail et al., 1989). The Rosner and Colditz model is another commonly used BC prediction
model developed in 1996 (Rosner et al., 1996). Poisson regression based prediction was later used
by including relevant breast tissue aging variables, such as age at menarche, age at first live birth,
and age at menopause into their model (Anothaisintawee et al., 2012). More recent prediction
models have modified the above two models by adding or removing certain predictive risk factors
to gain prediction accuracy (Cintolo-Gonzalez et al., 2017).
Besides the aforementioned non-genetic risk factors, genetic factors related to breast cancer risk
have also been studied for years. Family breast cancer history associated with germline mutations
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including variants in BRCA1 and BRCA2, as well as altered gene structure in other genes, such
asTP53, PTEN, ATM, CHEK2, NBS1, RAD50, BRIP, and PALB2, were thought to be involved
in cancer onset (Amir et al., 2010). BRCA1 and BRCA2 have long been linked to breast cancer.
Nevertheless, only 5 percent of the breast cancer cases at most could be explained by these high
penetrance genes, indicating that some of the low risk ‘susceptibility’ genes might play a role the
observed familial aggregation of breast cancer. (Tyrer et al., 2004) As a result, great efforts have
been made first to identify common genetic variants by means of genome wide association studies
(GWAS), and to incorporate these findings in order to improve the overall risk prediction
capacities for breast cancer in recent years (Hüsing et al., 2012).
Because of the significant clinical value associated with breast cancer risk predications models,
several of these models have been utilized for more individualized risk prediction by including
additional information on hormone use, family history, mode of inheritance of major genes, or
other genetic and non-genetic risk factors. Specifically, the Area Under the Curve (AUC) for
models using questionnaire-based risk factors, polygenic risk scores (PRS) built from 92 single
nucleotide polymorphisms (SNPs), and both types of risk factors was 0.588, 0.623, and 0.648,
respectively (Maas et al., 2016). Another study compared the prospective validation for PRSs
based on different numbers of SNPs, and the best PRS identified was conducted based on 313
SNPs and was significantly improved the prediction capacity than the previously reported 77-SNP
PRS (AUC 0.630 versus AUC 0.603) (Mavaddat et al., 2019). This suggests that a more
informative PRS would potentially achieve better risk prediction for breast cancer.
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In this study, by using large UK Biobank cohort data, we aim to develop a more comprehensive
breast cancer prediction model by combining both clinical factors and PRS to enable more accurate
breast cancer prediction in the general population.

Materials and Methods
Study Population
Case and Controls: The UK Biobank includes a prospective cohort with 503,000 participants
recruited in England, Scotland and Wales between 2006 and 2010. (http://www.ukbiobank.ac.uk.)
All participants were clinically followed up to March 1 2016. A total of 220,446 female
participants aged between 40 and 71 years old were identified from UK Biobank and included in
the study. BC cases were identified as the female participants having self-reported history of BC
(Self-report fields 20001(1002)), or cancer registration or death due to BC (ICD9 174, ICD10 C50).
Controls were identified as the female participants without any BC records throughout the whole
follow-up time. Among all the study participants, 13,581 were classified as BC cases and 206,865
were classified as controls (Supplementary Figure1. Case and control selection flow chart).
Exclusion criteria: 1. All male participants regardless of their breast cancer status; 2. All female
participants with incomplete records related to breast cancer.
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Clinical risk factors selection: By reviewing previous studies, we considered 19 candidate
clinical risk factors: age (Falkenberry and Legare, 2002), education years (Liu et al., 2017), income
status (Liu et al., 2016), Townsend Deprivation Index (TDI) (Said et al., 2018), BMI (Chan et al.,
2014), smoking (Falkenberry and Legare), hypertension (Han et al., 2017), alcohol using (Roswall
and Weiderpass, 2015), physical activity (Arem et al., 2015), and diet (Mourouti et al., 2015).
Family history factor only includes family history of breast cancer (on behalf of the BELE study
group et al., 2017). Reproductive factors include previous breast operations (Al-Ajmi et al., 2018),
menarche age, parity (Bilimoria and Morrow, 1995), age at first live birth (Bilimoria and Morrow,
1995), menopause status and menopause age (Li et al., 2017). Exogenous factors include duration
of oral contraceptive use (Gierisch et al., 2013) and history of hormone replacement therapy (Pizot
et al., 2016). Besides, we also considered socioeconomic conditions of UK Biobank women cohort.
The baseline demographic factor age and the first four genetic principle components (PC1-4) were
grouped as the adjustment factors (AD). All clinical factors were firstly tested using univariant
Cox regression model, the significant variables were then selected to be used in the final Clinical
Factor (CF) Model and the overall combined model.
PRS: We generated a set of candidate PRSs based on three PRS methods: P+T, LDPred and
AnnoPred, using the publicly available data from large-scale GWAS, in addition to a LD reference
panel consisted of 503 European samples from 1000 Phase 3 genome projects (Fritsche et al.,
2018). We also randomly sampled a training dataset of 73,120 females from the UK Biobank to
select the optimum PRS. We further calculated the optimum PRS based on the maximum AUC in
a Cox regression model with breast cancer diagnosis as the outcome, the candidate PRS as the
variable, and the onset age as the time factor. Finally, we estimated the confidence intervals for
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AUC using the ‘pROC’ package in R. The PRS with the best discrimination was included in the
final analyses.

Statistical Analysis
We firstly constructed univariate Cox proportional hazards regression models to assess the relative
risks (95%CIs) of all the clinical risk factors. Time to event started at the age recruited into the
study for both cases and controls, and ended at the age diagnosed with BC for cases and the age
completed follow-up. If death caused by competing events other than breast cancer had occurred
among the controls, time to event ended at death. Multiple imputation was used in this study for
missing data imputation by using the ‘Hmisc’ package in R, the process of which uses bootstraping
to draw predicted values based on a full Bayesian distribution.
Next, we used PRS calculated by AnnoPred based on 2,994,056 single nucleotide polymorphisms
(SNPs) as the genetic risk factor to conduct a second Cox regression prediction model, and then
we continuously added baseline population adjustment variables (age, PC1, PC2, PC3, PC4) and
all other non-genetic risk factors together to get a combined model. To be specific, we compared
the models including only clinical factors or PRS with a model with PRS plus adjustment factors
and all clinical factors step by step.

Models
To investigate the prediction effect of combined effects of clinical factors and PRS on breast cancer
risk, we considered the following four Cox proportional hazard models (Table 1):
8

1. Univariate Cox Regression Model: we fitted univariate Cox models for each of the 19
individual non-genetic risk factors: age, TDI, education years, BMI, smoking, hypertension,
alcohol using, income status, physical activity, diet, family history of breast cancer, previous
breast operations, menarche age, parity, age at first live birth, duration of OC use, menopause
status and menopause age, history of hormone replacement therapy (HRT).
2. Clinical Factor (CF) Model: we fitted a multivariate Cox model by including baseline
adjustment factors age and all individually significant non-genetic risk factors. Menopause
status was a stratified factor in the CF model which outputted a hazard ratio for menopause
age in the presence of hazard intrinsic to the post-menopause women.
3. PRS Model: we fitted a Cox regression model using PRS as the only predictor.
4. PRS + Adjustment (PRS + AD) Model: we fitted a Cox model adding AD factors (including
age and the first four principal components) in addition to PRS.
5. PRS + Clinical Factor (PRS + CF) Model: we finally fitted a Cox model by adding PRS and
the first four principal components into the Clinical Factor model to evaluate the overall
prediction accuracy by combining both genetic and non-genetic factors.

Metric used to evaluate prediction performance
We used Area Under the Curve (AUC, also known as c-statistic) to evaluate the performance of
different models. AUCs and their confidence intervals were calculated using the ‘pROC’ package
in R. The correlation of the predicted risks by the CF and PRS models was evaluated for
consistency between the two models. The cumulative risk of breast cancer was also calculated for
individuals in each risk category identified from the combined model.
9

Results
We first analyzed the baseline characteristics of potential risk factors to be included in the model
among the participants of the UK Biobank (Table 2). Of the total 220,442 participants finally
included in this study, 13,577 women were either diagnosed with BC during follow-up, or selfreported with previous BC history. The mean age of the study population was 56.7 years (SD, 7.9),
and the mean age of the case participants was 2.86 years older than that of the controls. A total of
136,082 (61.7%) were at the post-menopause stage and 84,360 (38.3%) were at the pre-menopause
stage; 203,003 (92.1%) women had no family history of breast cancer, while 17,439 (7.9%) women
self-reported with BC family history; 87,234 (39.6%) women reported with current hormone
replacement therapy (HRT), while 133,208 (60.4%) women were not receiving HRT. Among all
ag groups, the BC prevalence ranged from 1.9% to 7.8%, and the BC prevalence was above 5.5%
for participants aged between 55 and 70 (Figure 3). Group age 62 had the most BC cases (904 BC
patients out of 11,603 women aged 62, Prevalence 7.8%) and group age 40 had the least BC
patients (38 BC patients out of 1,964 women aged 40, Prevalence 1.89%), but group age 70 had
the highest prevalence of BC (Prevalence 9.4%, 94 BC cases and 906 controls) as expected.
Univariate Cox regression analysis was carried out for each classical non-genetic risk factor to
analyze its risk effect individually as shown in Table 3. All 19 non-genetic risk factors were
significantly associated with breast cancer on individual level including age (HR 1.47, 95%CI
1.44-1.49, p-value<0.001), TDI (HR 0.97, 95%CI 0.96-0.99, p-value<0.01), education years (HR
1.07, 95%CI 1.05-1.09, p-value<0.001), BMI (HR 1.05, 95%CI 1.03-1.07, p-value<0.001),
smoking (HR 1.04, 95%CI 1.01-1.07, p-value<0.001), hypertension (HR 1.30, 95%CI 1.25-1.34,
p-value<0.001), alcohol use (HR 0.96, 95%CI 0.92-0.99, p-value<0.05), income status (HR 1.12,
95%CI 1.11-1.14, p-value<0.001), physical activity (HR 1.09, 95%CI 1.05-1.13, p-value<0.001),
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family history of BC (HR 1.76, 95%CI 1.67-1.85, p-value<0.001), previous breast operations (HR
1.58, 95%CI 1.43-1.74, p-value<0.001), menarche age (HR 0.95, 95%CI 0.94-0.97, pvalue<0.001), parity (HR 0.97, 95%CI 0.95-0.99, p-value<0.001), age at first live birth (HR 1.01,
95%CI 1.00-1.04, p-value<0.05), contraceptive use (HR 0.76, 95%CI 0.73-0.79, p-value<0.001),
menopause (HR 1.85, 95%CI 1.78-1.93, p-value<0.001), menopause age (HR 0.94, 95%CI 0.930.94, p-value<0.001), and HRT (HR 1.08, 95%CI 1.05-1.12, p-value<0.001).
The results of multivariable Cox model (called Clinical Factor Model in the following discussion)
by including all non-genetic factors are shown in Table 4. In this CF Model, age, TDI, education
years, smoking, alcohol use, income status, physical activity, family history of breast cancer,
previous breast operations, menarche age, parity, age at first live birth, contraceptive use,
menopause age, and HRT were significantly associated with breast cancer diagnosis (𝛼=0.05, ttest p-values<0.05). According to the CF model, age was associated with increasing risk of
developing breast cancer (HR 2.07, 95%CI 2.01-2.13). Having higher TDI value and more
education years were both protective factors against breast cancer (TDI: HR 0.98, 95%CI 0.960.99; education years: HR 0.97, 95%CI 0.95-0.99). Having family history of breast cancer was
also strongly associated with higher risk of breast cancer (HR 1.78, 95%CI 1.70-1.88). Smoking
(HR 1.03), alcohol use (HR 1.05), and poor physical activities (HR 1.08) were also observed with
HRs exceeding 1. Women with previous breast operations including breast cyst/abscess removal
and breast biopsy (HR 1.40, 95%CI 1.27-1.55), and post-menopause women who had younger
menopause age (HR 0.91, 95%CI 0.90-0.91) had higher chance to develop breast cancer. Having
fewer live births, older age at first live birth, and not HRT were also strongly associated with
increased hazard of breast cancer diagnosis. The CF Model had an AUC value of 0.657 (95%CI
0.652-0.662).
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Three polygenic prediction methods were considered using publicly available external large-scale
GWAS summary statistics and UK Biobank: P+T, LDPred and AnnoPred. According to the P+T
method, for each pair of single nucleotide polymorphisms (SNPs) that have a physical distance
smaller than 250 kb and pairwise correlation greater than the provided R2T threshold, the algorithm
will remove the SNP with less significant effect-size. Of the SNPs that are remaining, the
individual PRS is then the effect-weighted sum of all remaining variants with their p-values below
a specific threshold, PT (PT: 1.0, 0.5, 0.05, 5E-4, 5E-6, 5E-8, R2T: 0.2, 0.4, 0.6, 0.8, 1.0). LDPred
is a Bayesian approach that infers the posterior mean effect size of each variant from GWAS
summary statistics while accounting for linkage disequilibrium (LD). This algorithm places an
independent point-normal prior on each effect-size and shrinks it based on LD information from a
reference panel. The underlying Gaussian distribution also considers the fraction of casual (i.e.
non-zero effect size) variants through a tuning parameter, p (p: 1.0, 0.3, 0.1, 0.03, 0.01, 3E-4, 1E4, 3E-5, 1E-5, 3E-6, 1E-6). AnnoPred is also a Bayesian framework based on GWAS summary
statistics. It firstly estimates GWAS signal enrichment in different annotation categories (4 types
of annotation are considered) for the trait analyzed. An empirical prior of SNP effect size is then
proposed based on the annotation assignment and signal enrichment, after which, the empirical
prior is jointly modeled with marginal summary statistics and LD matrix estimated from a
reference panel to infer the posterior effect size of each SNP. Here the fraction of casual variants
is also set as a tuning parameter, p (p: 1.0, 0.3, 0.1, 0.03, 0.01, 3E-4, 1E-4, 3E-5, 1E-5, 3E-6, 1E6).
The PRS score with the best discriminative capacity included in the PRS Model was determined
based on the maximal AUC in a cox regression model with the breast cancer as the outcome and
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the candidate PRS as the variable. Consistent with our previous results, AnnoPred outperformed
the other two methods with an AUC of 0.646 (95%CI 0.642-0.651) as shown in Figure 1.
The AUC for the PRS + AD Model which we got by combining PRS and adjustment variables
(AD) in the same model was 0.680 (95%CI 0.676-0.684), and for combined PRS + CF Model was
0.708 (95%CI 0.704-0.713). The AUCs and their corresponding 95%CIs for these models are
shown in Figure 2. By comparing the four AUC values, the PRS Model had the least risk
discrimination, CF Model had a better risk discrimination by increasing 5% unit AUC compared
to the PRS Model. The PRS + AD Model was the second best whose AUC was very close to the
PRS + CF Model, both of the two models had their AUC higher than 0.68. Adding adjustment
variables improved AUC of PRS Model from 0.646 to 0.680, and adding all the other 16
individually significant non-genetic variables increased AUC of the PRS + AD Model by 2.8%.
There was no overlap of the 95%CIs from different models.
Next, we computed age-stratified AUCs of the CF Model and the PRS Model separately to assess
the prediction accuracy stratified by age; and the coordination of the predicted high-risk
populations identified by different models were assessed through correlation analysis. Detailed
age-stratified AUC results are shown in Table 5.
The CF Model and PRS Model predicted in the different patterns when stratified by age. The AUC
of the CF Model varied from 0.593 to 0.971 and the AUC of the PRS Model varied from 0.602 to
0.680; and the correlation between the predictions from the two models varied between 1.66% and
4.70%. Figure 3 plots the age-stratified AUCs and the prediction correlation of the CF Model and
the PRS Model; and age specific breast cancer prevalence is also shown in Figure 3. As shown in
Figure 3, the CF Model and the PRS Model all achieved their best risk discrimination at age 4042. CF Model conducted a better prediction than PRS Model before age 56, but PRS Model had a
13

more stable risk discrimination through the overall age range compared to CF Model. However,
the correlation of the predicted risk population was less than 5% for all age-group women, which
indicated two exclusive high-risk populations had been identified by the two models.
Cumulative lifetime risk of developing breast cancer for different BC risk groups predicted by four
different models were estimated (Figure 4). The estimated risk of developing breast cancer by age
70 years for women in the lowest and highest 1% of the PRS Model was 1.1% (25 BC cases out
of 2,204 women) and 20.7% (456 BC cases out of 2,205 women), respectively. For the PRS + AD
Model, the estimated risk of developing breast cancer by age 70 years for women in the lowest
and highest 1% was 1.0% (21 cases out of 2,204 women) and 23.9% (528 cases out of 2,205
women). For the lowest and highest quintiles of the CF Model, the risk was 3.2% (70 cases out of
2,204 women) and 32.6% (718 cases out of 2,205 women) respectively. And the corresponding
risk of the PRS + CF Model was 1.4% (30 cases out of 2,204 women) and 40.1% (890 cases out
of 2,205 women).
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Discussion
This study conducts a comprehensive evaluation of the performance of different risk prediction
models for breast cancer including both genetic and non-genetic factors. All clinical risk factors
considered are well-established individual risk factors from previous studies except for TDI
(Nelson et al., 2013) (Sun et al., 2017) (Peterson and Ligibel, 2018), and they are all established
as significant breast cancer risk factors from the UK Biobank cohort as well. The results from the
univariate Cox regression models suggested that the incidence of breast cancer increased with age,
higher BMI, smoking, hypertension, poor income status, poor physical activity status, having first
degree relatives affected with breast cancer, having previous breast operations (breast cyst/abscess
removal or breast biopsy), late age at first live birth, post-menopause status, and with HRT use.
On the other hand, having more alcohol use, more educated years, poor diet, late menarche age,
more live births, contraceptive use, and late menopause age are protective against BC. Most of our
findings, except for alcohol use and contraceptive use status, are consistent with evidence
documented in other UK Biobank studies focusing on breast cancers (Al-Ajmi et al., 2018)(Lee et
al., 2019). According to previous studies, both alcohol use and contraceptive use are associated
with elevated breast cancer risk. One factor possibly contributing to these difference in results
related to alcohol use was the evenly distributed breast cancer patients in different smoking status
group; therefore, no obvious trend between smoking and breast cancer was available from the UK
Biobank. Furthermore, our study included women aged from 40 to 71, and 126,022 women (57.2%)
at the post-menopause status who were not current contraceptive users but had higher prevalence
of breast cancer. Therefore, a smaller proportion of current/previous contraceptive user among
breast cancer might be explained by the older age distribution of our study population
(Supplementary Figure 2). Besides, age-specific hazard ratios of all non-genetic predictors were
15

also analyzed. For modifiable predictive factors’ individually hazard ratios on breast cancer,
physical activity has been found with a specific age-specified trend in our study which haven’t
been well established (Supplementary Figure 2). Poor physical activity status started as a risk
factor for breast cancer, but ended as a protective factor for women age 60-70.
PRS has a comparative discrimination with all clinical factors on breast cancer prediction, as the
CF model has a slightly higher AUC = 0.657 (95%CI 0.652-0.663) than the PRS model (AUC =
0.646, 95%CI 0.642-0.651). However, after including population baseline information adjustment,
PRS has better performance than the models with only non-genetic risk factors (AUC 0.680,
95%CI 0.676-0.684). Combined model has the highest AUC equals to 0.708 (95%CI 0.704-0.713).
The risk discrimination provided by the genetic profile, summarized in the PRS and combined
with non-genetic risk factors improved the prediction model to the acceptable breast cancer
classifier.
Previous studies have developed numerous models for breast cancer risk prediction using various
risk factors. The Gail Model and Rosner-Colditz Model are the two most commonly used models
that initially included only lifestyle risk factors, reproductive risk factors and family history risk
factors. Over the past years, both models have been advanced and used to test for cancer risk in
the general population. Prediction accuracy had also increased as these breast cancer prediction
models evolved (Figure 5). The discrimination of our PRS + CF Model is comparable to the AUCs
calculated in past studies as a result of our inclusion of both the clinical factors and the newly
obtained PRS.
Even though the AUC differences across models are moderate, the predicted risk differences in
the top and bottom tails of the distribution are large, especially for the CF Model and the PRS +
CF Model. For the CF Model, the women in the top 1% of the distribution have a predicted risk
16

that is more than nine times the risk in the middle quintile, and approximately ten times the risk at
the bottom 1%. The cumulative lifetime risk of breast cancer among the top 1% women of the
distribution according to PRS + CF Model is about twenty-eight folds higher than that in the
bottom 1% women. Both the CF Model and the PRS + CF Model have more accurate prodictions
for the high-risk population. In comparison, the PRS Model performed better on the mediate
lifetime risk population. The top 1% risk women identified from the PRS Model have an eighteenfold predicted risk of breast cancer compared to the bottom 1% risk women, and a 2.72-fold
predicted risk compared with the median quintile.
There are several limitations of our study. Not all clinical risk factors considered in previous
studies are available from the UK Biobank; therefore, these factors could not be incorporated into
our current models. For example, when analyzing 52 epidemiologic studies (27), Nelson et al.
founded significantly increased breast cancer risk for women with first degree relatives had breast
cancer history (one relative RR 2.14; 95% CI 1.92–2.38; 2 relatives RR 3.84; 95% CI 2.37–6.22;
≥3 relatives RR 12.05; 95% CI 1.70–85.16) (Nelson et al., 2013). However, we could only include
information on whether an individual has a first degree relative diagnosed with breast cancer in
this study, but not other breast cancer family history information that has been found to be
significant in previous studies, including age at diagnosis of first-degree relatives with breast
cancer, the number of first degree relative diagnosed with breast cancer, and others. Breast density
is another important disease risk factor that could not be considered in our study. Women with
extensive mammographic density showed elevated risk for breast cancer, compared to their
counterparts with mammographic density below 10% (Odds Ratio 4.7, 95%CI 3.0 to 7.4) (Boyd
et al., 2007). In addition, breast feeding, a reproductive factor that has been found to have a
protective effect against breast cancer, was not available for analyses (Amir et al., 2010). Limited
17

access to non-genetic factors for the UK Biobank data might be one reason that only 2.8% unit
improvement of AUC was observed when adding all other non-genetic variables into the PRS +
AD Model. Future studies should test the validity of the proposed model with different racial or
ethnic groups.
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List of Tables
Table 1. Risk factors incorporated into established models
Model
Clinical Factors†

Adjustment
Factors¶

Genetic Factors

Univariate Model
√
Clinical Factor (CF) Model
√ + age
PRS Model
√
PRS + Adjustment (PRS + AD) Model
√
√
PRS + Clinical Factor (PRS + CF) Model
√
√
√
†Clinical factors: BMI, smoking, hypertension, alcohol using, physical activity, diet, family history of breast
cancer, previous breast operations, menarche age, parity, age at first live birth, duration of OC use, menopause
status and menopause age, history of hormone replacement therapy (HRT).
¶Adjustment factors: age, PC1, PC2, PC3, PC4.

Table 2. Baseline information of cases and controls in the UK Biobank
Characteristic
Cases
Number of cases and controls
13,577 (6.2%)
Personal factors
Age
Townsend deprivation index (TDI)
Education years (yrs)
No less than 19 years
Between 13 and 15 years
No more than 10 years
BMI
Underweight (< 18.5)
Healthy (18.5-24.9)
Overweight (25-29.9)
Obese (>= 30)
Smoking
Never smoke
Previous smoker
Current smoker
Hypertension
Yes
No
Alcohol use
Never use
Previous user
Current user
Income status (dollars)
Less than 18,000
18,000 to 30,999
31,000 to 51,999
52,000 to 100,000

Controls
206,865 (93.8%)

59.39
-1.66

56.53
-1.58

5,260 (94.3%)
2,749 (93.5%)
5,434 (93.5%)

87,030 (5.7%)
39,495 (6.5%)
78,487 (6.5%)

83 (5.4%)
4,905 (5.8%)
5,317 (6.5%)
3,237 (6.3%)

1,452 (94.6%)
79,839 (94.2%)
76,711 (93.5%)
48,286 (93.7%)

7,714 (5.9%)
4,734 (6.8%)
1,075 (5.6%)

122,792 (94.1%)
65,372 (93.2%)
17,994 (94.4%)

7,455 (5.6%)
6,122 (6.2%)

99,879 (94.4%)
106,986 (93.8%)

651 (6.7%)
494 (6.2%)
12,424 (6.1%)

9,023 (93.3%)
7,452 (93.8%)
190,255 (93.9%)

3,158 (7.0%)
3,186 (6.5%)
2,603 (5.6%)
1,672 (4.9%)

41,693 (93%)
45,673 (93.5%)
44,153 (94.4%)
32,218 (95.1%)
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Greater than 100,000
Physical activity
Poor
Ideal
Diet
Poor
Ideal
Family history factors
Family history of breast cancer
Yes
No
Reproductive factors
Previous breast operations
Yes
No
Menarche age
Between 5 and 12
13
14
15 and above
Number of live births
0
1
2
>=3
Age at first live birth
19 and below
Between 20 and 24
Between 25 and 29
30 and above
Contraceptive use (years)
Never
Previous
Current
Menopause
Yes
No
Menopause age
Hormone replacement therapy (HRT)
Yes
No

426 (5.1%)

7,979 (94.9%)

3,474 (6.6%)
10,103 (6.0%)

49,493 (93.4%)
157,372 (94.0%)

10994 (6.1%)
2587 (6.6%)

170091 (93.9%)
36774 (93.4%)

1,746 (10.0%)
11,831 (5.8%)

15,693 (90.0%)
191,172 (94.2%)

383 (9.3%)
13,194 (6.1%)

3,719 (90.7%)
203,146 (93.9%)

5,497 (6.6%)
3,113 (6.0%)
2,624 (6.1%)
1,993 (5.6%)

78,342 (93.4%)
49,154 (94.0%)
40,105 (93.9%)
33,551 (94.4%)

2,549 (6.4%)
1,801 (6.2%)
6,222 (6.2%)
2,996 (5.8%)

37,283 (93.6%)
27,028 (93.8%)
93,551 (93.8%)
48,885 (94.2%)

813 (5.4%)
3,301 (6.2%)
3,607 (6.3%)
4,041 (6.2%)

14,125 (94.6%)
50,208 (93.8%)
53,954 (93.7%)
61,299 (93.8%)

2,896 (7.5%)
10,545 (5.9%)
117 (3.0%)

35,920 (92.5%)
166,752 (94.1%)
3,835 (97.0%)

10,107 (7.4%)
3,470 (4.1%)
50.06

125,975 (92.6%)
80,890 (95.9%)
53.31

5,634 (6.5%)
7,906 (6.0%)

81,600 (93.5%)
124,782 (94.0%)
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Table 3. Univariable cox regression model, hazard ratio of BC among women from UK Biobank, N=220,442
Variable
HR
95% CI
P-value
Age
1.47
1.44-1.49
0.0e+00***
TDI
0.97
0.96-0.99
2.6e-03**
Education years
1.07
1.05-1.09
4.2e-12***
BMI
1.05
1.03-1.07
9.4e-06***
Smoking
1.04
1.01-1.07
2.4e-03**
Hypertension
1.30
1.25-1.34
0.0e+00***
Alcohol use
0.96
0.92-0.99
2.1e-02*
Income status
1.12
1.11-1.14
0.0e+00***
Physical activity
1.09
1.05-1.13
1.3e-05***
Diet
0.92
0.88-0.96
1.3e-04***
Family history of BC
1.76
1.67-1.85
0.0e+00***
Previous breast operations
1.58
1.43-1.74
0.0e+00***
Menarche age
0.95
0.94-0.97
2.3e-09***
Parity
0.97
0.95-0.99
2.7e-04***
Age at first live birth
1.01
1.00-1.04
2.9e-02*
Menopause
1.85
1.78-1.93
0.0e+00***
Menopause age
0.94
0.93-0.94
0.0e+00***
Contraceptive use
0.76
0.73-0.79
0.0e+00***
HRT
1.08
1.05-1.12
4.9e-06***
*

p-values<0.05 **p-values<0.01***p-values<0.001.
Dashed lines grouped variables into 4 categories: personal and lifestyle factors, family history factors, reproductive factors,
exogenous factors.

Table 4. Multivariable Cox regression model, hazard ratio of BC among women from UK Biobank,
N=220,442
Variable
HR
95% CI
P-value
Age
2.07
2.01-2.13
0.0e+00***
TDI
0.98
0.96-0.99
8.9e-03**
Education years
0.97
0.95-0.99
9.3e-03**
BMI
1.02
1.00-1.04
8.3e-02
Smoking
1.03
1.01-1.06
1.2e-02*
Hypertension
1.03
1.00-1.07
8.0e-02
Alcohol use
1.05
1.01-1.09
7.6e-03**
Income status
0.98
0.96-1.00
4.5e-02*
Physical activity
1.08
1.04-1.13
4.7e-05***
Diet
0.96
0.92-1.01
8.8e-02
Family history of BC
1.79
1.71-1.89
0.0e+00***
Previous breast operations
1.41
1.27-1.55
3.4e-11***
Menarche age
0.95
0.94-0.97
4.8e-09***
Parity
0.97
0.95-1.00
4.0e-03**
Age at first live birth
1.08
1.05-1.10
2.5e-08***
Contraceptive use
1.08
1.04-1.13
1.3e-04***
Menopause Age
0.92
0.92-0.92
0.0e+00***
HRT
0.78
0.75-0.80
0.0e+00***
*

p-values<0.05 **p-values<0.01***p-values<0.001.
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Table 5. Age-stratified AUC of the CF Model and the PRS Model and their prediction correlation.
AUC
Age
Prevalence(%)
CF Model
PRS Model
Correlation(%)
[40,42]
2.3
0.971
0.680
2.09
[42,44]
2.8
0.942
0.602
1.66
[44,46]
3.4
0.927
0.667
3.72
[46,48]
3.7
0.906
0.634
4.20
[48,50]
4.2
0.815
0.639
4.70
[50,52]
4.6
0.756
0.662
3.11
[52,54]
5.0
0.709
0.665
3.10
[54,56]
5.8
0.664
0.630
2.34
[56,58]
6.4
0.625
0.644
1.85
[58,60]
6.9
0.634
0.649
3.25
[60,62]
7.4
0.618
0.644
2.85
[62,64]
8.4
0.607
0.651
3.15
[64,66]
8.4
0.605
0.647
3.04
[66,68]
9.2
0.593
0.651
3.01
[68,70]
8.7
0.611
0.647
4.31
[70,71]
9.4
0.645
0.645
3.26
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List of Figures

Figure 1. AUC comparison of PRS for breast cancer.

Figure 2. AUC and CI comparison across models. (CF) Clinical Factor Model; (PRS) PRS Model; (PRS+AD) PRS
+ Adjustment Model; (PRS + CF) PRS + Clinical Factor Model.
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Figure 3. (A) Age-adjusted AUCs and prediction correlation (B) Age Distribution of breast cancer
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Figure 4. Cumulative risk of breast cancer predicted by models.
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Figure 5. AUC comparisons across different risk prediction models from published studies. (1) Zhang modified
Rosner, 2018 (Zhang et al., 2018); (2) Zhang modified Gail, 2018 (Zhang et al., 2018); (3) Tworoger, 2014 (Tworoger
et al., 2014); (4) Tice, 2008 (Tice et al., 2013); (5) SNP-based, 2017 (Dite et al., 2016);(6) Petracci, 2011 (Petracci et
al., 2011); (7) MyCathy, 2015 (McCarthy et al., 2015); (8) Care Model, 2007 (Adams-Campbell et al., 2007); (9)
BRCAPRO, 2016 (Dite et al., 2016); (10) BOADICEA, 2016 (Dite et al., 2016); (11) BOADICEA and SNP-based,
2016 (Dite et al., 2016); (12) BBD_BC, 2015 (Pankratz et al., 2015).
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Appendices
Missing Value Imputation
We noticed that 13 non-genetic factors had incomplete collected data. The proportion of missing
data varies across predictors from 0.05% to 16.23%. TDI has 243 incomplete cases (ICs), and
missing rate (MR) equals to 0.11%; education years has 1891 ICs (MR=0.86%); BMI has 587 ICs
(MR=0.27%); smoking has 720 ICs (MR=0.33%); alcohol use has 135 ICs (MR=0.06%); income
status has 35,846 ICs (MR=16.26%); menarche age has 5,815 ICs (MR=2.64%); parity has 121
ICs (MR=0.05%); first birth age has 29,094 ICs (MR=13.20%); OC use duration has 366 ICs
(MR=0.17%); menopause status has 159 ICs (MR=0.07%); menopause age has 9,023 ICs
(MR=4.09%); HRT has 497 ICs (MR=0.23%).
According to our UK Biobank breast cancer dataset, the missing data mechanism can be
considered as missing at random (MAR), because the probability that any value is missing only
depends on whether the clinical information was available when the data was collected initially
(García-Laencina et al., 2015). Multiple imputation (MI) is effective at providing
(asymptotically) unbiased estimates of the regression parameter of interest (e.g., log odds, log
relative risk) when data are MAR (Harel et al., 2018). R package ‘Hmisc’ was used to conduct
multiple imputation on predictors’ missing values using additive regression, bootstrapping, and
predictive mean matching.
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Figures

407,122 observations available
from UK Biobank

186,676 male participants
were excluded from this study
(including 97 male BC cases
and 186,579 male controls)
220,446 female participants left in
this study

4 female participants with
incomplete records related to
breast cancer were excluded
from this study

220,442 female participants were
eventually included in this study

Supplementary Figure 1. Case and control selection flow chart
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Supplementary Figure 2. The age-specific hazard ratios by breast cancer predictors
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